- Johnson and Johnson (J&J) has confirmed plans of partnering the Biomedical Advanced Research and Development Authority (BARDA) to find a vaccine for COVID-19
- The $1 billion partnership follows a previous agreement between BARDA and J&J-owned Janssen Pharmaceutical Company
- Areas to be covered in the partnership include research and development of potential antiviral treatments
Top pharmaceutical company, Johnson and Johnson (J&J), is set to partner with the Biomedical Advanced Research and Development Authority (BARDA) to fund a $1 billion vaccine research to provide a cure for the coronavirus.
BARDA is part of the United States of America (USA)’s Department of Health and Human Services.
Briefly.co.za understands that the partnership is an expansion of a previous agreement between BARDA and the J&J-owned Janssen Pharmaceutical Company.
Techcrunch reports that the agreement would result in the provision of the global supply of over a billion doses of the vaccine.
The partnership is expected to cover areas such as research and development of potential antiviral treatments, as well as the work being done to develop a vaccine for the virus.
In other news, a new type of test which has been developed by scientists in the United Kingdom (UK) could help detect the coronavirus in about 30 minutes.
The scientists are from Brunel University London, Lancaster University and the University of Surrey.
The procedure involves the use of hand-held hardware that costs an estimated $120 and comes with individual swab sample kits that cost $5 per person.
The test follows the principles of an existing technology that was popular in the Philippines for testing viral spread in chickens.
Enjoyed reading our story? Download BRIEFLY’s news app on Google Play now and stay up-to-date with major South African news!